Literature DB >> 25698314

ADAMTS proteases in vascular biology.

Juan Carlos Rodríguez-Manzaneque1, Rubén Fernández-Rodríguez2, Francisco Javier Rodríguez-Baena2, M Luisa Iruela-Arispe3.   

Abstract

ADAMTS (a disintegrin and metalloprotease with thrombospondin motifs) proteases comprise the most recently discovered branch of the extracellular metalloenzymes. Research during the last 15years, uncovered their association with a variety of physiological and pathological processes including blood coagulation, tissue repair, fertility, arthritis and cancer. Importantly, a frequent feature of ADAMTS enzymes relates to their effects on vascular-related phenomena, including angiogenesis. Their specific roles in vascular biology have been clarified by information on their expression profiles and substrate specificity. Through their catalytic activity, ADAMTS proteases modify rather than degrade extracellular proteins. They predominantly target proteoglycans and glycoproteins abundant in the basement membrane, therefore their broad contributions to the vasculature should not come as a surprise. Furthermore, in addition to their proteolytic functions, non-enzymatic roles for ADAMTS have also been identified expanding our understanding on the multiple activities of these enzymes in vascular-related processes.
Copyright © 2015. Published by Elsevier B.V.

Entities:  

Keywords:  ADAMTS; angiogenesis; extracellular proteolysis; vasculature

Mesh:

Substances:

Year:  2015        PMID: 25698314      PMCID: PMC8086761          DOI: 10.1016/j.matbio.2015.02.004

Source DB:  PubMed          Journal:  Matrix Biol        ISSN: 0945-053X            Impact factor:   11.583


  51 in total

1.  The first but not the second thrombospondin type 1 repeat of ADAMTS5 functions as an angiogenesis inhibitor.

Authors:  Soheila Sharghi-Namini; Huapeng Fan; K N Sulochana; Padma Potturi; Wei Xiang; Yap-Seng Chong; Zhengyuan Wang; He Yang; Ruowen Ge
Journal:  Biochem Biophys Res Commun       Date:  2008-04-21       Impact factor: 3.575

2.  ADAMTS1 cleavage of versican mediates essential structural remodeling of the ovarian follicle and cumulus-oocyte matrix during ovulation in mice.

Authors:  Hannah M Brown; Kylie R Dunning; Rebecca L Robker; Derek Boerboom; Melanie Pritchard; Michelle Lane; Darryl L Russell
Journal:  Biol Reprod       Date:  2010-06-30       Impact factor: 4.285

3.  Androgen regulates ADAMTS15 gene expression in prostate cancer cells.

Authors:  Chidi N Molokwu; Olajumoke O Adeniji; Shankar Chandrasekharan; Freddie C Hamdy; David J Buttle
Journal:  Cancer Invest       Date:  2010-08       Impact factor: 2.176

4.  METH-1, a human ortholog of ADAMTS-1, and METH-2 are members of a new family of proteins with angio-inhibitory activity.

Authors:  F Vázquez; G Hastings; M A Ortega; T F Lane; S Oikemus; M Lombardo; M L Iruela-Arispe
Journal:  J Biol Chem       Date:  1999-08-13       Impact factor: 5.157

5.  ADAMTS1/METH1 inhibits endothelial cell proliferation by direct binding and sequestration of VEGF165.

Authors:  Alfonso Luque; Darren R Carpizo; M Luisa Iruela-Arispe
Journal:  J Biol Chem       Date:  2003-04-25       Impact factor: 5.157

6.  ADAMTS4 and its proteolytic fragments differentially affect melanoma growth and angiogenesis in mice.

Authors:  Nithya Rao; Zhiyuan Ke; Hongrui Liu; Chao-Jin Ho; Saran Kumar; Wei Xiang; Yizhun Zhu; Ruowen Ge
Journal:  Int J Cancer       Date:  2013-02-12       Impact factor: 7.396

7.  The ADAMTS12 metalloproteinase exhibits anti-tumorigenic properties through modulation of the Ras-dependent ERK signalling pathway.

Authors:  María Llamazares; Alvaro J Obaya; Angela Moncada-Pazos; Ritva Heljasvaara; Jesús Espada; Carlos López-Otín; Santiago Cal
Journal:  J Cell Sci       Date:  2007-09-25       Impact factor: 5.285

8.  ADAMTS1 is a unique hypoxic early response gene expressed by endothelial cells.

Authors:  Omer F Hatipoglu; Satoshi Hirohata; M Zeynel Cilek; Hiroko Ogawa; Toru Miyoshi; Masanari Obika; Kadir Demircan; Ryoko Shinohata; Shozo Kusachi; Yoshifumi Ninomiya
Journal:  J Biol Chem       Date:  2009-04-06       Impact factor: 5.157

Review 9.  Metalloproteinases and their inhibitors in tumor angiogenesis.

Authors:  Madeleine M Handsley; Dylan R Edwards
Journal:  Int J Cancer       Date:  2005-07-20       Impact factor: 7.396

10.  Tumour angiogenesis is reduced in the Tc1 mouse model of Down's syndrome.

Authors:  Louise E Reynolds; Alan R Watson; Marianne Baker; Tania A Jones; Gabriela D'Amico; Stephen D Robinson; Carine Joffre; Sarah Garrido-Urbani; Juan Carlos Rodriguez-Manzaneque; Estefanía Martino-Echarri; Michel Aurrand-Lions; Denise Sheer; Franca Dagna-Bricarelli; Dean Nizetic; Christopher J McCabe; Andrew S Turnell; Stephanie Kermorgant; Beat A Imhof; Ralf Adams; Elizabeth M C Fisher; Victor L J Tybulewicz; Ian R Hart; Kairbaan M Hodivala-Dilke
Journal:  Nature       Date:  2010-06-10       Impact factor: 49.962

View more
  21 in total

1.  Expression of ADAMTS13 in Normal and Abnormal Placentae and Its Potential Role in Angiogenesis and Placenta Development.

Authors:  Juan Xiao; Yun Feng; Xueyin Li; Wei Li; Lei Fan; Jing Liu; Xue Zeng; Kaiyue Chen; Xi Chen; Xiaoshui Zhou; X Long Zheng; Suhua Chen
Journal:  Arterioscler Thromb Vasc Biol       Date:  2017-07-27       Impact factor: 8.311

2.  The extracellular metalloprotease AdamTS-A anchors neural lineages in place within and preserves the architecture of the central nervous system.

Authors:  James B Skeath; Beth A Wilson; Selena E Romero; Mark J Snee; Yi Zhu; Haluk Lacin
Journal:  Development       Date:  2017-07-31       Impact factor: 6.868

3.  ADAMTS18+ villus tip telocytes maintain a polarized VEGFA signaling domain and fenestrations in nutrient-absorbing intestinal blood vessels.

Authors:  Jeremiah Bernier-Latmani; Cristina Mauri; Rachel Marcone; François Renevey; Stephan Durot; Liqun He; Michael Vanlandewijck; Catherine Maclachlan; Suzel Davanture; Nicola Zamboni; Graham W Knott; Sanjiv A Luther; Christer Betsholtz; Mauro Delorenzi; Cathrin Brisken; Tatiana V Petrova
Journal:  Nat Commun       Date:  2022-07-09       Impact factor: 17.694

Review 4.  ADAMTS13: more than a regulator of thrombosis.

Authors:  Yun Feng; Xueyin Li; Juan Xiao; Wei Li; Jing Liu; Xue Zeng; Xi Chen; Suhua Chen
Journal:  Int J Hematol       Date:  2016-10-01       Impact factor: 2.490

5.  C/EBPβ and Nuclear Factor of Activated T Cells Differentially Regulate Adamts-1 Induction by Stimuli Associated with Vascular Remodeling.

Authors:  Jorge Oller; Arántzazu Alfranca; Nerea Méndez-Barbero; Silvia Villahoz; Noelia Lozano-Vidal; Mara Martín-Alonso; Alicia G Arroyo; Amelia Escolano; Angel Luis Armesilla; Miguel R Campanero; Juan Miguel Redondo
Journal:  Mol Cell Biol       Date:  2015-07-27       Impact factor: 4.272

Review 6.  Scarring vs. functional healing: Matrix-based strategies to regulate tissue repair.

Authors:  Timothy J Keane; Christine-Maria Horejs; Molly M Stevens
Journal:  Adv Drug Deliv Rev       Date:  2018-02-06       Impact factor: 15.470

7.  Hydrocephalus in mouse B3glct mutants is likely caused by defects in multiple B3GLCT substrates in ependymal cells and subcommissural organ.

Authors:  Sanjiv Neupane; June Goto; Steven J Berardinelli; Atsuko Ito; Robert S Haltiwanger; Bernadette C Holdener
Journal:  Glycobiology       Date:  2021-09-09       Impact factor: 4.313

Review 8.  The ADAMTS (A Disintegrin and Metalloproteinase with Thrombospondin motifs) family.

Authors:  Richard Kelwick; Ines Desanlis; Grant N Wheeler; Dylan R Edwards
Journal:  Genome Biol       Date:  2015-05-30       Impact factor: 13.583

9.  Cleavage of Fibulin-2 by the aggrecanases ADAMTS-4 and ADAMTS-5 contributes to the tumorigenic potential of breast cancer cells.

Authors:  Tania Fontanil; Saúl Álvarez-Teijeiro; M Ángeles Villaronga; Yamina Mohamedi; Laura Solares; Angela Moncada-Pazos; José A Vega; Olivia García-Suárez; Marcos Pérez-Basterrechea; Juana M García-Pedrero; Alvaro J Obaya; Santiago Cal
Journal:  Oncotarget       Date:  2017-02-21

10.  Stroma-derived but not tumor ADAMTS1 is a main driver of tumor growth and metastasis.

Authors:  Rubén Fernández-Rodríguez; Francisco Javier Rodríguez-Baena; Estefanía Martino-Echarri; Carlos Peris-Torres; María Del Carmen Plaza-Calonge; Juan Carlos Rodríguez-Manzaneque
Journal:  Oncotarget       Date:  2016-06-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.